Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3FH02)

Drug Name
Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate Drug Info
Synonyms
2-(Morpholin-4-yl)-benzo[h]chromen-4-one; 154447-35-5; NU7026; NU 7026; DNA-PK Inhibitor II; NU-7026; 2-morpholino-4H-benzo[h]chromen-4-one; LY293646; LY-293646; 2-(4-Morpholinyl)-4H-naphthol[1,2-b]pyran-4-one; 2-(4-morpholinyl)-4H-naphtho[1,2-b]pyran-4-one; CHEMBL104468; AK186905; DNA-Dependent Protein Kinase Inhibitor II; 2-morpholin-4-ylbenzo[h]chromen-4-one; SCHEMBL610237; ZINC9230; GTPL5959; KS-00000XHI; CTK0E7833; CHEBI:92165; DTXSID10432010; AOB2835; MolPort-009-019-548; HMS3229C11; EX-A1100; BCP04736; IN1364; s2893
Cross-matching ID
PubChem CID
9860529
ChEBI ID
CHEMBL92165
CAS Number
CAS 154447-35-5
TTD Drug ID
D0W1ST

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.24 0.00e+0 34/36 (94.44%) PCNA;MCM5;MCM2;...
Cell cycle 1.93 1.60e-2 110/124 (88.71%) CDC25B;PCNA;MCM5;...
Mineral absorption -1.69 4.27e-2 48/60 (80%) SLC31A1;TRPV6;SLC34A2;...
Propanoate metabolism -1.70 3.93e-2 30/34 (88.24%) ALDH6A1;ACSS3;SUCLG2;...
Proteasome -1.73 2.89e-2 44/46 (95.65%) PSMB7;PSMD13;PSMB10;...
Other glycan degradation -1.73 2.58e-2 13/18 (72.22%) HEXB;MAN2B1;HEXA;...
Glutathione metabolism -1.74 2.70e-2 43/57 (75.44%) CHAC1;IDH1;GGT1;...
Vibrio cholerae infection -1.75 2.52e-2 44/50 (88%) SEC61B;PDIA4;KCNQ1;...
Antigen processing and presentation -1.78 2.55e-2 60/78 (76.92%) TAP1;CD4;HLA-DQA1;...
Protein processing in endoplasmic reticulum -1.81 1.93e-2 127/171 (74.27%) ERN1;DDOST;SEC61B;...
Steroid biosynthesis -1.85 1.30e-2 19/20 (95%) SOAT1;LIPA;MSMO1;...
Amino sugar and nucleotide sugar metabolism -1.88 9.92e-3 38/48 (79.17%) PGM3;NPL;NANS;...
Lysosome -1.91 5.79e-3 115/128 (89.84%) CLTA;MANBA;CTSG;...
Biosynthesis of unsaturated fatty acids -1.96 2.31e-3 21/27 (77.78%) ELOVL1;BAAT;ACOX3;...
Ferroptosis -1.96 2.89e-3 36/41 (87.8%) SLC11A2;LPCAT3;SLC39A8;...
Rheumatoid arthritis -1.99 3.86e-3 78/93 (83.87%) IL23A;ATP6V1H;CXCL2;...
Epithelial cell signaling in Helicobacter pylori infect... -2.01 5.79e-3 62/70 (88.57%) PAK1;ATP6V1E1;PLCG2;...
IL-17 signaling pathway -2.08 1.16e-2 84/94 (89.36%) MAPK10;FOSL1;JUN;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H